#Carbapenem

[msinsights]

Carbapenem Market Size, Share, Growth Prospects, Top Vendors, End Users and Forecast by 2031

The Carbapenem Market, as analyzed by Metastat Insight, presents a fascinating landscape characterized by its dynamic nature and significant impact on the healthcare sector. Carbapenems, a class of antibiotics renowned for their broad-spectrum activity against a wide range of bacteria, have emerged as essential weapons in the fight against infectious diseases. In recent years, the market for carbapenems has witnessed notable growth driven by factors such as the increasing prevalence of antibiotic-resistant bacteria, rising incidence of hospital-acquired infections, and the growing demand for effective treatment options. This essay delves into the various aspects of the Global Carbapenem market, exploring its current state, trends, challenges, and future prospects. Global Carbapenem market is estimated to reach $2,473.9 million in 2024 with a CAGR of 5.3% from 2024 to 2031. 

Get Free Sample Report @ https://www.metastatinsight.com/request-sample/2736

Top Companies

Pfizer, Savior Lifetec, Sun Pharmaceutical Industries, Kopran, HISUN Pharmaceutical, Shenzhen Haibin Pharmaceutical Co. Ltd., ACS Dobfar S.P.A., Daewoong Pharmaceutical Co., Iterum Therapeutics plc Lupin Imipenem.

The Global Carbapenem market’s report by Metastat Insight encompasses a diverse range of products and formulations, including imipenem, meropenem, ertapenem, and doripenem, among others. These antibiotics are widely used in clinical settings to combat serious infections caused by multidrug-resistant bacteria, including Gram-negative and Gram-positive organisms. Their efficacy, coupled with a relatively low incidence of resistance, has solidified their position as critical components of antibiotic therapy regimens across different medical specialties. 

One of the primary drivers fueling the growth of the Global Carbapenem market is the escalating threat of antimicrobial resistance (AMR). As bacteria continue to develop mechanisms to evade the effects of conventional antibiotics, carbapenems have emerged as indispensable tools in the clinician's arsenal. Their broad spectrum of activity and ability to penetrate bacterial cell walls make them effective against a wide range of pathogens, including those resistant to other antibiotic classes. Consequently, healthcare providers increasingly rely on carbapenems to treat severe infections that are unresponsive to other antibiotics, thereby driving market demand. 

Browse Complete Report @ https://www.metastatinsight.com/report/carbapenem-market

The rising incidence of hospital-acquired infections (HAIs) also contributes significantly to the demand for carbapenems. In healthcare settings, where patients are often immunocompromised and susceptible to infections, carbapenems play a crucial role in managing complicated infections such as ventilator-associated pneumonia, bloodstream infections, and intra-abdominal infections. Their ability to penetrate tissues and achieve high concentrations at the site of infection makes them invaluable in the treatment of critically ill patients, underscoring their importance in clinical practice.

[mindblowingscience]

Researchers have identified an entirely new class of antibiotic that can kill bacteria that are resistant to most current drugs. Zosurabalpin is highly effective against the bacterium carbapenem-resistant Acinetobacter baumannii (Crab), which is classified as a "priority 1" pathogen by the World Health Organization due to its growing presence in hospitals.

Continue Reading.

[thedee-n]

Bacillus licheniformis:

This is a gram positive bacterium commonly found in soil. It’s found on bird feathers especially chest and back plumage. It’s common in ground dwelling birds too. Is it harmful to man ? Yes it is has been found to cause infection in several cases of immunocompromised patients. It’s the causative agent of ventriculitis, ophthalmitis, bacteremia and endocarditis.

Treatment: it is sensitive to antibiotics such as cefepime, carbapenems, aminoglycosides and vancomycin.

…. Health is wealth …

[flyonthewallmedstudent]

Finegoldia magna

Cold open with a case report:

60M with a past history of previous wrist fracture presents with worsening pain and swelling, erythema and reduced range of motion, after suffering an abrasion from changing a tire.

the previous injury resulted from an MVA 9 yrs prior with a closed rist fracture

there was also a history of ETOH use and possible malnutrition, which can result in immunosuppression

Xray showed extensive changes in the wrist bones compared to past years with near loss of several, suggestive of pyogenic arthritis

Aspiration of the wrist joint grew Finegoldia magna

What is it

not actually uncommon

but is more commonly associated with post op infections or prosthetic joint infections (so case reports are harder to find in this category)

previously known as peptostreptococcus (sounds like peptobismol) but was renamed following 16S rna sequence availability, so in older texts/articles you'll still see it's old name

it's a commensal, so normal part of our microflora, but is opportunistic like so many other pathogens we usually live with and covers our body

It is a Gram Positive Anaerobe, of the same flavour of clostridium. Remember there's fewer gram positive anaerobes than there are aerobes. So consider it in cultures if there's only growth in the anaerobe bottle and it's gram positive (purple). Usually it likes mucosal surfaces, such as the GI or GU tracts, but it doesn't mind skin either. It's considered a "gram positive anaerobic cocci" (GPAC) and has increasing prevalence and antibiotic resistance in the group.

Image source

Increased risk and when to think of it

chronic ulcers, diabetic ulcers

associated with biofilms (always bad, requires prolonged duration of antibiotics)

prosthetic joints

prosthetic valves

as it is opportunistic, also consider it in the immunocompromised

In the case above, the patient had septic arthritis, for which anaerobes account for 20% of cases. And Finegoldia is often the culprit in the case of post op and prosthetic joint infections. Rarely affects normal joints or healed joints from previous closed trauma years prior.

In chronic wounds it can impair healing via Protein L, which bindings to antibodies, causing immunomodulatory effect.

Bit of history

named for Sydney Finegold, an American physician who was a founding member of IDSA (infectious diseases society of American) and one of its early former presidents

but the name did make me think of 'fine gold'

Treatment

luckily susceptible to penicillin - but there is growing resistance, hence relevance of always chasing susceptibility

alternatives: metronidazole (typical class that covers anaerobes), tazocin and carbapenems

also has increasing resistance to clindamycin (a consideration in penicillin allergy or during empirical therapy for wounds)

Resources:

case report

wikipaedia

microbe canvas

[xipiti]

Another person has died in an outbreak of extensively drug-resistant bacteria linked to contaminated eye drops, the Centers for Disease Control and Prevention reported in an update on Thursday.

The outbreak now totals 81 cases across 18 states. In addition to the four deaths, health officials have tallied reports of 14 people with vision loss and an additional four people who have had their eyeballs surgically removed (enucleation) due to infection.

The bacteria behind the outbreak is a strain of Pseudomonas aeruginosa dubbed VIM-GES-CRPA. This unwieldy acronym stands for a carbapenem-resistant P. aeruginosa (CRPA) with Verona integron-mediated metallo-β-lactamase (VIM) and Guiana extended-spectrum-β-lactamase (GES). It is an extensively drug-resistant strain of bacteria that, until this outbreak, had never been seen in the US before.

US health officials have traced the bacteria's origins to contaminated eye drops, with EzriCare artificial tears being the most common product used by people infected during the outbreak. The Food and Drug Administration reported a recall of these drops in February after the CDC released a health alert about 55 cases and the link to the eye drops. The manufacturer of EzriCare eye drops, India-based Global Pharma, also recalled two other products it makes: Delsam Pharma’s Artificial Tears and Delsam Pharma’s Artificial Ointment. The CDC and the FDA advise people to stop using these products immediately if they haven't already.

Before the recalls, the eye drops were readily available nationwide and sold through Amazon, Walmart, eBay, and other retailers. Clinical samples indicate the contamination spans from at least May 2022 to April 2023, though the CDC has advised health care professionals to report any suspect clinical samples dating back to January 2022.

This week's outbreak update includes 13 new cases since the last outbreak update in March, six of which had samples collected prior to the recall and are now confirmed and added to the tally. Of the seven other newly added cases, most either resided in long-term care facilities with other known cases or reported continued use of one of the recalled artificial tears, the CDC reported. Another person has died in an outbreak of extensively drug-resistant bacteria linked to contaminated eye drops, the Centers for Disease Control and Prevention reported in an update on Thursday.

The outbreak now totals 81 cases across 18 states. In addition to the four deaths, health officials have tallied reports of 14 people with vision loss and an additional four people who have had their eyeballs surgically removed (enucleation) due to infection.

The bacteria behind the outbreak is a strain of Pseudomonas aeruginosa dubbed VIM-GES-CRPA. This unwieldy acronym stands for a carbapenem-resistant P. aeruginosa (CRPA) with Verona integron-mediated metallo-β-lactamase (VIM) and Guiana extended-spectrum-β-lactamase (GES). It is an extensively drug-resistant strain of bacteria that, until this outbreak, had never been seen in the US before.

US health officials have traced the bacteria's origins to contaminated eye drops, with EzriCare artificial tears being the most common product used by people infected during the outbreak. The Food and Drug Administration reported a recall of these drops in February after the CDC released a health alert about 55 cases and the link to the eye drops. The manufacturer of EzriCare eye drops, India-based Global Pharma, also recalled two other products it makes: Delsam Pharma’s Artificial Tears and Delsam Pharma’s Artificial Ointment. The CDC and the FDA advise people to stop using these products immediately if they haven't already.

Before the recalls, the eye drops were readily available nationwide and sold through Amazon, Walmart, eBay, and other retailers. Clinical samples indicate the contamination spans from at least May 2022 to April 2023, though the CDC has advised health care professionals to report any suspect clinical samples dating back to January 2022.

This week's outbreak update includes 13 new cases since the last outbreak update in March, six of which had samples collected prior to the recall and are now confirmed and added to the tally. Of the seven other newly added cases, most either resided in long-term care facilities with other known cases or reported continued use of one of the recalled artificial tears, the CDC reported.

[reality-detective]

The manufacturer of a brand of over-the- counter eye drops said that it was recalling the product, EzriCare Artificial Tears, after it was linked to a drug-resistant bacteria strain that has caused at least one person's death and vision loss in five others.

The Centers for Disease Control and Prevention has advised people to stop using the eye drops, as the agency investigates an outbreak of a strain of the bacteria pseudomonas aeruginosa, which can cause infections in the blood, lungs and other parts of the body. This strain of the bacteria had never been identified in the United States before the current outbreak and is resistant to a class of antibiotics called carbapenems, which are generally considered a last resort.

The bacteria strain had been found in 55 people in 12 states as of Tuesday, the C.D.C. said. The agency said that the infections had caused one death, vision loss in five of 11 people who had eye infections, and some hospitalizations.

Another Note👇

They stop this but let a vaxxine known to cause multiple adverse effects and tens of thousands of deaths continue to be used. History has shown inoculations we're stopped after 25 adverse reactions and or deaths.

Does this even make sense to you?🤔

[teachingrounds]

CRE = Carbapenem-Resistant Enterobacteriaceae. Carbapenems are a newer class of beta-lactamase antibiotics; CRE bacteria may also be resistant to unrelated drugs such as fluoroquinolones. Enterobacteriaceae is the name of a family of Gram-negative bacteria (E. coli, Klebsiella, Salmonella, etc.), many of which live in the human gut. Some patients came down with CRE after being scoped with the same endoscope as another patient with CRE in their stomach, intestines, or lungs. This category includes bacteria that have certain resistance factors such as KPC , NDM-1, and VIM. Treat with old and/or toxic drugs such as polymyxins, fosfomycin, and (sometimes) aminoglycosides (susceptibility varies).

• KPC = Klebsiella pneumoniae carbapenemase. A resistance factor that helps bacteria survive carbapenems and other beta-lactamase antibiotics. There was an outbreak in an NIH hospital.

• NDM-1 = New Delhi Metallobeta-lactamase 1. First identified in India and now in 140 countries, this plasmid moves promiscuously among different species of bacteria. Bad news for wound infections, pneumonias, meningitis, and blood infections.

• VIM = Verona Integron-Mediated Metallo-betalactamase. Like NDM-1, makes bugs resistant to beta-lactamase antibiotics such as penicillin or ceftriaxone.

[hawkeyedflame]

Gas station kombucha? Well, i always did want to try a carbapenem

[aingopharma]

Introduction of the Faropenem Sodium Tablets 200 mg

Faropenem Sodium Tablets 200 mg have been making waves in the medical community as an effective treatment for various bacterial infections. Whether it’s respiratory, urinary tract, or skin infections, this antibiotic has shown promise in combating resistant bacteria. In this article, we’ll delve into what makes Faropenem Sodium Tablets so effective, how they work, their potential benefits and side effects, and important precautions to consider.

What are Faropenem Sodium Tablets 200 mg?

Faropenem Sodium is a broad-spectrum antibiotic belonging to the carbapenem class, specifically used to treat a wide range of bacterial infections. These tablets contain 200 mg of Faropenem, which works by inhibiting the synthesis of bacterial cell walls. This action effectively kills bacteria and helps clear infections from the body.

How Do Faropenem Sodium Tablets 200 mg Work?

Faropenem targets the penicillin-binding proteins (PBPs) in bacteria, essential for cell wall synthesis. By binding to these proteins, the antibiotic disrupts the bacterial cell wall’s structure, leading to the bacteria’s death. This mechanism is particularly effective against gram-positive and gram-negative bacteria, making Faropenem a versatile option for treating infections.

Uses of Faropenem Sodium Tablets 200 mg

Faropenem Sodium Tablets 200 mg are commonly prescribed for:

Respiratory Tract Infections: These include conditions like bronchitis, pneumonia, and sinusitis. Faropenem helps eliminate the bacteria causing these ailments, allowing for a quicker recovery.

Urinary Tract Infections (UTIs): This antibiotic is effective against common pathogens causing UTIs, such as Escherichia coli.

Skin and Soft Tissue Infections: Faropenem can treat cellulitis, abscesses, and other skin infections caused by bacteria.

Gynecological Infections: It’s sometimes used to manage pelvic inflammatory disease and other bacterial infections in the reproductive system.

Ear Infections: Faropenem is effective against otitis media and other bacterial infections of the ear.

[creativeera]

Acute Bacterial Skin And Skin Structure Infections Market Trends driven by Increasing Antibiotic Resistance

The acute bacterial skin and skin structure infections (ABSSSI) market comprises anti-infective drugs that are used to treat skin infections caused by bacteria. These infections include impetigo, cellulitis, wound infections, and major cutaneous abscesses. The commonly prescribed drugs are antibiotics such as cephalosporins, carbapenems, lipoglycopeptides, oxazolidinones, and tetracyclines. The increasing threat of antimicrobial resistance (AMR) has boosted the demand for effective antibiotic treatments. Growing prevalence of skin infections owing to rising environmental pollution levels and lifestyle changes has also augmented market growth.

Global acute bacterial skin and skin structure infections market is estimated to be valued at USD 3,842.5 Mn in 2024 and is expected to reach USD 5,701.7 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.8% from 2024 to 2031.

Key Takeaways Key players operating in the Acute Bacterial Skin And Skin Structure Infections market are Fresenius SE and Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GSK plc, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics LLC, Accord Healthcare Ltd., Merck and Co., Inc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc. The growing prevalence of skin infections across the world coupled with the rising threat of AMR is fueling the demand for effective antibiotic therapies. Leading market players are investing in R&D to develop novel drugs with new mechanisms of action. On the other hand, companies are also undertaking initiatives to expand their presence in emerging economies through strategic partnerships and acquisition activities. The Acute Bacterial Skin And Skin Structure Infections Market Demand rising threat of antimicrobial resistance is a key concern that is augmenting the demand for novel and effective anti-infective treatments for ABSSSIs. According to the WHO, drug-resistant bacteria could cause 10 million deaths annually by 2050 if adequate actions are not taken. Growing awareness regarding antibiotic stewardship practices is reducing the irrational use of antibiotics to some extent. However, further regulatory interventions and strict prescribing guidelines are required to curb the development and spread of resistant pathogens. Market Key Trends One of the major trends witnessed in the acute bacterial skin and skin structure infections market is the rising focus on developing new antibiotic classes with novel mechanisms of action to overcome anti-microbial resistance. Several pipeline drugs under clinical trials employ new mechanisms like inhibition of bacterial DNA/RNA synthesis, cell wall biosynthesis, and protein synthesis. Monoclonal antibodies targeting specific toxins produced by resistant bacteria is another novel area being explored. Fast track approvals and commercialization of path-breaking antibiotic therapies will ensure long-term market sustenance amid growing healthcare costs and stringent pricing control by governments globally.

Porter's Analysis Threat of new entrants: New players find it difficult to enter this market owing to high costs of R&D and regulatory requirements. Bargaining power of buyers: Many buyers have low bargaining power due to lack of alternatives. Bargaining power of suppliers: Suppliers have moderate bargaining power due to availability of substitute sources. Threat of new substitutes: Threat from new substitutes is moderate due to technology developments and increasing investments in alternatives. Competitive rivalry: Fierce competition exists among existing players to gain market share. Geographical Regions North America accounts for the largest share of the global acute bacterial skin and skin structure infections market, in terms of value, followed by Europe. This is attributed to the rapidly growing incidence of skin infections, advanced healthcare infrastructure, favorable reimbursement policies, and high awareness among healthcare professionals and patients regarding diagnosis and treatment. Asia Pacific is expected to witness the fastest growth during the forecast period, primarily driven by improving access to healthcare facilities owing to rising disposable incomes, growing incidence of skin infections due to changing lifestyles, and supportive government policies and initiatives in emerging economies. Rising medical tourism in Asian countries has also boosted the market growth in the region.

Get more insights on Acute Bacterial Skin And Skin Structure Infections Market

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

[crimsonpublishers-medical]

Escherichia coli Harboring Mcr-1 on a Novel Plasmid in a Mink in Eastern China- Crimson Publishers

Escherichia coli Harboring Mcr-1 on a Novel Plasmid in a Mink in Eastern China- Crimson Publishers

In the current study, we described the characterization of an mcr-1-positive E. coli isolate from a dead mink in Dongping Lake, China. The molecular characterization of plasmids was also investigated. The strain was resistant to colistin, but it remained susceptible to several other agents, including amikacin, piperacillin-tazobactam, all carbapenems, and ESBLs. E. coli Mink_1 belonged to sequence type 140. Whole Genome Sequencing (WGS) showed that two plasmids, pM1mcr and pM1ctx, coexisted in the same bacterial. Blast and phylogenetic tree imply that Epidemic plasmids are vehicles for the dissemination of colistin resistance genes among the Enterobacterales. Restrictive use of antibiotics in animal husbandry should be taken to reduce the dissemination of mcr-1.

For more open access journals in crimson publishers Please click on link: https://crimsonpublishers.com

For more articles on Research in Medical & Engineering Sciences Please click on link: https://crimsonpublishers.com/rmes/

[eggtrolls]

You know I got that crab (carbapenem-resistant Acinetobacter baumannii) in me